相似文献
1
High-Dimensional Analysis Delineates Myeloid and Lymphoid Compartment Remodeling during Successful Immune-Checkpoint Cancer Therapy.
Cell. 2018 Nov 15;175(5):1443. doi: 10.1016/j.cell.2018.11.003.
2
Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors.
Front Immunol. 2018 Jun 11;9:1310. doi: 10.3389/fimmu.2018.01310. eCollection 2018.
3
Propelling Immunotherapy Combinations Into the Clinic.
Oncology (Williston Park). 2015 Dec;29(12):990-1002.
4
Extracellular matrix and the myeloid-in-myeloma compartment: balancing tolerogenic and immunogenic inflammation in the myeloma niche.
J Leukoc Biol. 2017 Aug;102(2):265-275. doi: 10.1189/jlb.3MR1116-468R. Epub 2017 Mar 2.
5
Immune checkpoint pathways: perspectives on myeloid malignancies.
Leuk Lymphoma. 2016 May;57(5):995-1001. doi: 10.3109/10428194.2015.1107554. Epub 2016 Feb 25.
6
Immune Checkpoint Molecules on Tumor-Infiltrating Lymphocytes and Their Association with Tertiary Lymphoid Structures in Human Breast Cancer.
Front Immunol. 2017 Oct 30;8:1412. doi: 10.3389/fimmu.2017.01412. eCollection 2017.
7
The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer.
Immunol Rev. 2017 Mar;276(1):145-164. doi: 10.1111/imr.12527.
8
Alemtuzumab treatment alters circulating innate immune cells in multiple sclerosis.
Neurol Neuroimmunol Neuroinflamm. 2016 Oct 12;3(6):e289. doi: 10.1212/NXI.0000000000000289. eCollection 2016 Dec.
9
Cytokine Networks between Innate Lymphoid Cells and Myeloid Cells.
Front Immunol. 2018 Feb 7;9:191. doi: 10.3389/fimmu.2018.00191. eCollection 2018.
10
FAP positive fibroblasts induce immune checkpoint blockade resistance in colorectal cancer via promoting immunosuppression.
Biochem Biophys Res Commun. 2017 May 20;487(1):8-14. doi: 10.1016/j.bbrc.2017.03.039. Epub 2017 Mar 14.
引用本文的文献
1
Modulation of the immune microenvironment using nanomaterials: a new strategy for tumor immunotherapy.
Front Immunol. 2025 Jul 2;16:1614640. doi: 10.3389/fimmu.2025.1614640. eCollection 2025.
2
CyTOF as a suitable tool for stratification and monitoring of cancer patients.
J Transl Med. 2025 Jul 1;23(1):724. doi: 10.1186/s12967-025-06764-0.
3
In vivo labelling resolves distinct temporal, spatial, and functional properties of tumour macrophages, and identifies subset-specific effects of PD-L1 blockade.
Cancer Immunol Res. 2025 Jun 16. doi: 10.1158/2326-6066.CIR-24-1233.
4
Cold and hot tumors: from molecular mechanisms to targeted therapy.
Signal Transduct Target Ther. 2024 Oct 18;9(1):274. doi: 10.1038/s41392-024-01979-x.
5
Phenotyping Tumor Heterogeneity through Proteogenomics: Study Models and Challenges.
Int J Mol Sci. 2024 Aug 14;25(16):8830. doi: 10.3390/ijms25168830.
6
Host-derived Interleukin 1α induces an immunosuppressive tumor microenvironment via regulating monocyte-to-macrophage differentiation.
bioRxiv. 2024 May 5:2024.05.03.592354. doi: 10.1101/2024.05.03.592354.
7
Reprogramming of tumor-associated macrophages via NEDD4-mediated CSF1R degradation by targeting USP18.
Cell Rep. 2023 Dec 26;42(12):113560. doi: 10.1016/j.celrep.2023.113560. Epub 2023 Dec 13.
8
Immunotherapy Enhancement by Targeting Extracellular Tumor pH in Triple-Negative Breast Cancer Mouse Model.
Cancers (Basel). 2023 Oct 11;15(20):4931. doi: 10.3390/cancers15204931.
9
The CX3CL1-CX3CR1 chemokine axis can contribute to tumor immune evasion and blockade with a novel CX3CR1 monoclonal antibody enhances response to anti-PD-1 immunotherapy.
Front Immunol. 2023 Sep 13;14:1237715. doi: 10.3389/fimmu.2023.1237715. eCollection 2023.
10
Targeting TREM1 augments antitumor T cell immunity by inhibiting myeloid-derived suppressor cells and restraining anti-PD-1 resistance.
J Clin Invest. 2023 Nov 1;133(21):e167951. doi: 10.1172/JCI167951.
Zotero 插件